REFLECT

NCT01761266 📎

Regimen

Experimental
lenvatinib (12 mg/day if >=60 kg; 8 mg/day if <60 kg)
Control
sorafenib

Population

Unresectable hepatocellular carcinoma, Child-Pugh A, no prior systemic therapy

Key finding

mOS 13.6 vs 12.3 mo (HR 0.92, 95% CI 0.79-1.06) — **noninferiority met, superiority NOT met**; lenva superior mPFS 7.4 vs 3.7 mo and ORR 24% vs 9% (mRECIST); different toxicity profiles (lenva=HTN/diarrhea; sora=PPE)

Source: PMID 29433850

Timeline

    Guideline citations

    • NCCN HCC (p.28)